Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Raw Materials (2021 - 2025)

Veracyte (VCYT) has disclosed Raw Materials for 5 consecutive years, with $20.5 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 14.94% to $20.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, up 14.94% year-over-year, with the annual reading at $20.5 million for FY2025, 14.94% up from the prior year.
  • Raw Materials hit $20.5 million in Q4 2025 for Veracyte, up from $20.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $20.5 million in Q4 2025 to a low of $3.0 million in Q4 2021.
  • Historically, Raw Materials has averaged $9.6 million across 5 years, with a median of $4.4 million in 2022.
  • Biggest five-year swings in Raw Materials: decreased 6.82% in 2023 and later soared 346.9% in 2024.
  • Year by year, Raw Materials stood at $3.0 million in 2021, then soared by 36.67% to $4.1 million in 2022, then decreased by 2.44% to $4.0 million in 2023, then skyrocketed by 346.9% to $17.9 million in 2024, then grew by 14.94% to $20.5 million in 2025.
  • Business Quant data shows Raw Materials for VCYT at $20.5 million in Q4 2025, $20.3 million in Q3 2025, and $20.1 million in Q2 2025.